四价灭活流感疫苗在3至17岁健康受试者中的免疫原性与安全性:一项III期、开放标签、单臂研究
本研究在2016-2017流感季评估了台湾生产的四价灭活流感疫苗AdimFlu-S在174名3至17岁健康儿童中的免疫原性与安全性,受试者分为3组。末次接种后4周,四种疫苗株的几何平均滴度比在2.9至20.9之间,血清转换率在42.9%至90.9%之间,血清保护率均高于96.4%,达到所有免疫原性终点并符合欧洲药品管理局人用药品委员会(CHMP)标准。6个月随访期内未报告严重不良事件,该疫苗耐受性良好且对各流感株显示稳健免疫原性。
要点
- 末次接种后4周,四种疫苗株的血清保护率均高于96.4%。
- 几何平均滴度比在2.9至20.9之间,血清转换率在42.9%至90.9%之间。
- 6个月随访期内未报告严重不良事件。
核心结论
- 该四价流感疫苗耐受性良好,对每种流感株均显示稳健免疫原性,可能改善针对抗原性不同的B/Yamagata和B/Victoria系的保护。
研究设计与样本
- III期、开放标签、单臂研究,纳入174名3至17岁健康儿童,分为3组(A组:3-8岁,疫苗未接种过;B组:3-8岁,疫苗曾接种过;C组:9-17岁,任何接种状态),每人接种前后采集血清,采用血凝抑制试验计算几何平均滴度、血清保护率和血清转换率。
主要发现
- 所有入组受试者均完成研究,末次接种后4周,四种疫苗株的几何平均滴度比在2.9至20.9之间。
- 末次接种后4周,血清转换率在42.9%至90.9%之间,血清保护率均高于96.4%。
- 6个月随访期内未报告严重不良事件。
关键数值与推荐
- 达到所有免疫原性终点并符合欧洲药品管理局人用药品委员会(CHMP)标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quadrivalent influenza vaccines are particularly valuable during seasons in which a mismatch occurs between the predicted influenza B lineage for the trivalent influenza vaccine and the circulating strain. This study evaluated the immunogenicity and safety of a quadrivalent inactivated influenza vaccine AdimFlu-S manufactured in Taiwan for the 2016-2017 influenza season in healthy children. METHODS: A total of 174 healthy children aged 3 to 17 years old were separated into 3 groups (Group A: 3-8 years old, vaccine naïve; Group B: 3-8 years old, vaccine non-naïve; Group C: 9-17 years old, any vaccine status). Sera was collected pre and post vaccination for each participant. A hemagglutination inhibition (HAI) assay was utilized to calculate geometric mean titer (GMT), seroprotection rate, and seroconversion rate. RESULTS: All enrolled participants completed the study. For the four vaccine strains four weeks after the last vaccination, geometric mean titer ratios (GMTRs) were between 2.9 and 20.9, seroconversion rates were between 42.9% and 90.9%, and seroprotection rates were all above 96.4%. This achieved all immunogenicity endpoints and fulfilled the criteria of the European Medical Agency's Committee for Medicinal Products for Human Use (CHMP). No serious adverse events (AEs) were reported during the follow-up period of 6 months. CONCLUSION: This quadrivalent influenza vaccine is demonstrated to be well tolerated and displays robust immunogenicity for each influenza strain. This could potentially improve protection against the antigenically distinct B/Yamagata and B/Victoria lineages.
引用
- Chang CY, Cho CY, Lai CC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study. Vaccine. 2020. PMID: 32284272. doi:10.1016/j.vaccine.2020.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。